Skip to main content
Erschienen in: International Urology and Nephrology 4/2010

01.12.2010 | Urology – Original Paper

The impact of core biopsy fragmentation in prostate cancer

verfasst von: Leonardo Oliveira Reis, José Alberto Salvo Reinato, Daniel Carlos Silva, Wagner Eduardo Matheus, Fernandes Denardi, Ubirajara Ferreira

Erschienen in: International Urology and Nephrology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Since accurate tumor localization and quantification are essential requisites avoiding prostate cancer overtreatment, we analyzed the impact of core fragmentation and the relation between core biopsy taken and pathological information in regard to cancer extension and aggressiveness (Gleason score).

Methods

One hundred and ninety-nine men submitted to trans-rectal prostate biopsy by the same urologist between October 2006 and October 2008 were included, and the number of cores obtained by biopsy compared to the number of cores examined by the same pathologist.

Results

Total core number obtained by biopsy was 21.54 (±3.56) compared to 24.08 (±4.77) examined by the pathologist, P < 0.01. Dividing prostate gland by areas such as base, mid and apical right and left, all areas showed statistically different core number between biopsy and pathological examination report (P < 0.01). Mean ratio of positive core cancer length was 0.41 (±0.12) and 0.32 (±0.8) comparing individual and overall cores analysis, respectively (P < 0.01). The mean Gleason score in the individual and overall cores analysis were 6.6 (6–9) and 6.3 (6–9), respectively, P < 0.01.

Conclusions

Considering the ongoing trend for earlier diagnosis of increasing numbers of younger men with low-risk prostate cancer, this study is original and demonstrates the possibility of core fragmentation, explaining in part over- and under-staging. One core per container and an overall Gleason score and percentage of adenocarcinoma for each container are encouraged.
Literatur
1.
Zurück zum Zitat Eggener SE, Scardino PT, Carroll PR et al (2007) Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178:2260–2267CrossRefPubMed Eggener SE, Scardino PT, Carroll PR et al (2007) Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178:2260–2267CrossRefPubMed
2.
3.
Zurück zum Zitat Presti JC Jr, Chang JJ, Bhargava V et al (2000) The optimal systematic prostate biopsy scheme should include eight rather than six biopsies: results of a prospective clinical trial. J Urol 163:163–167CrossRefPubMed Presti JC Jr, Chang JJ, Bhargava V et al (2000) The optimal systematic prostate biopsy scheme should include eight rather than six biopsies: results of a prospective clinical trial. J Urol 163:163–167CrossRefPubMed
4.
Zurück zum Zitat Eskicorapci SY, Guliyev F, Akdogan B et al (2005) Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 173:1536–1540CrossRefPubMed Eskicorapci SY, Guliyev F, Akdogan B et al (2005) Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 173:1536–1540CrossRefPubMed
5.
Zurück zum Zitat O’Connell MJ, Smith CS, Fitzpatrick PE et al (2004) et Transrectal ultrasound-guided biopsy of the prostate gland: value of 12 vs. 6 cores. Abdom Imag 29:132–136CrossRef O’Connell MJ, Smith CS, Fitzpatrick PE et al (2004) et Transrectal ultrasound-guided biopsy of the prostate gland: value of 12 vs. 6 cores. Abdom Imag 29:132–136CrossRef
6.
Zurück zum Zitat Inahara M, Suzuki H, Kojima S et al (2006) Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology 68:815–819CrossRefPubMed Inahara M, Suzuki H, Kojima S et al (2006) Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology 68:815–819CrossRefPubMed
7.
Zurück zum Zitat Ubhayakar GN, Li WY, Corbishley CM et al (2002) Improving glandular coverage during prostate biopsy using a long-core needle: technical performance of an end-cutting needle. BJU Int 89:40–43CrossRefPubMed Ubhayakar GN, Li WY, Corbishley CM et al (2002) Improving glandular coverage during prostate biopsy using a long-core needle: technical performance of an end-cutting needle. BJU Int 89:40–43CrossRefPubMed
8.
Zurück zum Zitat Dogan HS, Eskicorapci SY, Ertoy-Baydar D et al (2005) Can we obtain better specimens with an end-cutting prostatic biopsy device? Eur Urol 47:297–301CrossRefPubMed Dogan HS, Eskicorapci SY, Ertoy-Baydar D et al (2005) Can we obtain better specimens with an end-cutting prostatic biopsy device? Eur Urol 47:297–301CrossRefPubMed
9.
Zurück zum Zitat Häggarth L, Ekman P, Egevad L (2002) A new core-biopsy instrument with an end-cut technique provides prostate biopsies with increased tissue yield. BJU Int 90:51–55CrossRefPubMed Häggarth L, Ekman P, Egevad L (2002) A new core-biopsy instrument with an end-cut technique provides prostate biopsies with increased tissue yield. BJU Int 90:51–55CrossRefPubMed
10.
Zurück zum Zitat Ozden E, Göğüş C, Tulunay O, Baltaci S (2004) The long core needle with an end-cut technique for prostate biopsy: does it really have advantages compared with standard needles? Eur Urol 45:287–291CrossRefPubMed Ozden E, Göğüş C, Tulunay O, Baltaci S (2004) The long core needle with an end-cut technique for prostate biopsy: does it really have advantages compared with standard needles? Eur Urol 45:287–291CrossRefPubMed
11.
Zurück zum Zitat Brimo F, Vollmer RT, Corcos J et al (2008) Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 53:177–183CrossRefPubMed Brimo F, Vollmer RT, Corcos J et al (2008) Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 53:177–183CrossRefPubMed
12.
Zurück zum Zitat Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H (2000) The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163:174–178CrossRefPubMed Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H (2000) The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163:174–178CrossRefPubMed
13.
Zurück zum Zitat Cheng L, Jones TD, Pan CX et al (2005) Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18:1022–1026CrossRefPubMed Cheng L, Jones TD, Pan CX et al (2005) Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18:1022–1026CrossRefPubMed
14.
Zurück zum Zitat Moore RA (1935) The morphology of small prostatic carcinomas. J Urol 33:224–234 Moore RA (1935) The morphology of small prostatic carcinomas. J Urol 33:224–234
15.
Zurück zum Zitat Goto Y, Ohori M, Arakawa A et al (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156:1059–1063CrossRefPubMed Goto Y, Ohori M, Arakawa A et al (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156:1059–1063CrossRefPubMed
16.
Zurück zum Zitat Wise AM, Stamey TA, McNeal JE et al (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60:264–269CrossRefPubMed Wise AM, Stamey TA, McNeal JE et al (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60:264–269CrossRefPubMed
17.
Zurück zum Zitat Kattan MW, Shariat SF, Andrews B et al (2003) The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21:3573–3579CrossRefPubMed Kattan MW, Shariat SF, Andrews B et al (2003) The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21:3573–3579CrossRefPubMed
18.
Zurück zum Zitat Graefen M, Karakiewicz PI, Cagiannos I et al (2002) International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20:3206–3212CrossRefPubMed Graefen M, Karakiewicz PI, Cagiannos I et al (2002) International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 20:3206–3212CrossRefPubMed
19.
Zurück zum Zitat Gardiner RA, Hamdy FC (2008) Management of low-risk prostate cancer. World J Urol 26:411–414CrossRefPubMed Gardiner RA, Hamdy FC (2008) Management of low-risk prostate cancer. World J Urol 26:411–414CrossRefPubMed
20.
Zurück zum Zitat Epstein JI, Walsh PC, Carmichael M et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRefPubMed Epstein JI, Walsh PC, Carmichael M et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRefPubMed
21.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (2000) Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164–1172PubMed D’Amico AV, Whittington R, Malkowicz SB et al (2000) Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164–1172PubMed
22.
Zurück zum Zitat Freedland SJ, Terris MK, Csathy GS et al (2004) Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 171:2215–2220CrossRefPubMed Freedland SJ, Terris MK, Csathy GS et al (2004) Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 171:2215–2220CrossRefPubMed
23.
Zurück zum Zitat Epstein JI, Allsbrook WC, Amin MB, Egevad LL, the ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed Epstein JI, Allsbrook WC, Amin MB, Egevad LL, the ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed
25.
Zurück zum Zitat Gupta C, Ren JZ, Wojno KJ (2004) Individual submission and embedding of prostate biopsies decreases rates of equivocal pathology reports. Urology 63:83–86CrossRefPubMed Gupta C, Ren JZ, Wojno KJ (2004) Individual submission and embedding of prostate biopsies decreases rates of equivocal pathology reports. Urology 63:83–86CrossRefPubMed
Metadaten
Titel
The impact of core biopsy fragmentation in prostate cancer
verfasst von
Leonardo Oliveira Reis
José Alberto Salvo Reinato
Daniel Carlos Silva
Wagner Eduardo Matheus
Fernandes Denardi
Ubirajara Ferreira
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2010
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9720-0

Weitere Artikel der Ausgabe 4/2010

International Urology and Nephrology 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.